Recent advances in the field of anti-cancer immunotherapy

BBA Clinical

Volumn 3, Issue , 2015, Pages 280-288

  Neves, Henrique ^a   Kwok, Hang Fai ^a  

^a University of Macau   (Macao)

Author keywords

Anti cancer therapies; Antibodies; Cancer; Immunotherapy

Indexed keywords

CATHEPSIN S; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; NUCLEIC ACID; RITUXIMAB; TRASTUZUMAB; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UROKINASE;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL INVASION; CELL TRANSFER; CYTOTOXICITY; DENDRITIC CELL; GENE AMPLIFICATION; GENE EXPRESSION; IMMUNOREACTIVITY; NEOPLASM; NERVE DEGENERATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SEQUENCE HOMOLOGY; SOLUBILIZATION; THERAPY EFFECT; TUMOR GROWTH;

EID: 84928314046     PISSN: 22146474     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbacli.2015.04.001     Document Type: Review

References (77)

1. Fauvel B., Yasri A. Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer. mAbs 2014, 6(4):10-11.
2. Stern M., Herrman R. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit. Rev. Oncol. Hematol. 2005, 56(1):11-59.
3. Nadler L.M., et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 1980, 40:3147-3154.
4. Sharkey R.M., Goldenberg D.M. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J. Clin. 2006, 56:226-243.
5. Kahl B. Chemotherapy combinations with monoclonal antibodies in non-Hodgkin's lymphoma. Semin. Hematol. 2008, 45(2):90-94.
6. Rosenberg S.A., et al. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 2004, 45(2):909-915.
7. Baeuerle P.A., Reindhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009, 69:4941.
8. Shahied L.S., et al. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J. Biol. Chem. 2004, 279:53907-53914.
9. Chames P., et al. Therapeutic antibodies: successes, limitations and hopes for the future. Br. J. Pharmacol. 2009, 157(2):220-233.
10. Oldham R.K., Dillman R.O. Monoclonal antibodies in cancer therapy: 25years of progress. J. Clin. Oncol. 2008, 26(11):1774-1777.
11. Tape C.J., et al. Cross-domain inhibition of TACE ectodomain. PNAS 2011, 108(14).
12. Moss M.L., et al. Cloning of a disintegrin metalloproteinase that processes precursor tumor-necrosis factor-alpha. Nature 1997, 385:733-736.
13. Black R.A., et al. A metalloproteinase disintegrin that releases tumour-necrosis. Nature 1997, 385:729-733.
14. Sunnarborg S.W., et al. Tumor necrosis factor-alpha converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability. J. Biol. Chem. 2002, 277:12838-12845.
15. Brou C., et al. A novel proteolytic cleavage involved in Notch signalling: the role of the disintegrin-metalloprotease TACE. Mol. Cell 2000, 5:207-216.
16. Condon T.P., et al. ADAM17 but not ADAM 10 mediates tumor necrosis factor-alpha and L-selectin shedding from leukocyte membranes. Antisense Nucleic Acid Drug Dev. 2001, 11:107-116.
17. Marin V., et al. Chemotactic agents induce IL-6Ralpha shedding from polymorphonuclear cells: involvement of a metalloproteinase of the TNF-alpha-converting enzyme (TACE) type. Eur. J. Immunol. 2002, 32(10):2965-2970.
18. Kenny P.A. TACE: a new target in epidermal growth factor receptor dependent tumors. Differentiation 2007, 75:800-808.
19. Moss M.L., Sklair-Tavron L., Nudelman R. Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 2008, 4:300-309.
20. Saftig P., Reiss K. The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: novel drug targets with therapeutic potential?. Eur. J. Cell Biol. 2011, 90:527-535.
21. Richards F., et al. Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo. PLoS ONE 2012, 7(7):e40597.
22. Kwok H.F., et al. Development of a 'mouse and human cross-reactive' affinity-matured exosite inhibitory human antibody specific to TACE (ADAM17) for cancer immunotherapy. Protein Eng. Des. Sel. 2014, 27(6):1-12.
23. Bostrom J., et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009, 323:1610-1614.
24. Gao J., Sidhu S.S., Wells J.A. Two-state selection of conformation-specific antibodies. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:3071-3076.
25. Hu X., et al. Combinatorial libraries against libraries for selecting neoepitope activation-specific antibodies. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:6252-6257.
26. Willems S., et al. Thiol isomerases negatively regulate the cellular shedding activity of ADAM17. Biochem. J. 2010, 428:439-450.
27. Edwards D.R., Handsley M.M., Pennington C.J. The ADAM metalloproteinases. Mol. Asp. Med. 2008, 29(5):258-289.
28. Kenny P.A., Bissell M.J. Targeting TACE-dependent EGFR ligand shedding in breast cancer. J. Clin. Invest. 2007, 117(2):337-345.
29. Burden R. Antibody targeting of Cathepsin S induces antibody-dependent cellular cytotoxicity. Mol. Cancer 2011, 10:147.
30. Kwok H.F. Antibody research targeting Cathepsin S for cancer therapy. Adv. Biosci. Biotechnol. 2013, 4:17-20.
31. Verderio P. Synthesis and Biofunctionalization of Novel Composite Nanocarriers for Targeted Detection and Treatment of Malignant Cells 2014, (PhD thesis).
32. X.X., et al. Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM). PLoS ONE 2014, 9(1):e85349.
33. Burden R.E., et al. Antibody-mediated inhibition of Cathepsin S blocks colorectal tumor invasion and angiogenesis. Clin. Cancer Res. 2009, 15.
34. Maloney D.G., et al. DEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. BloodSep 1997, 90(6):2188-2195.
35. Li M., et al. Nanoscale distribution of Cd20 on B-cell lymphoma tumour cells and its potential role in the clinical efficacy of Rituximab[J]. J. Microsc. 2014, 254(1):19-30.
36. Leandro M.J. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res. Ther. 2013, 15(Supplement 1):S3.
37. Van Der Kolk L.E., et al. Complement activation plays a key role in the side-effects of rituximab treatment. Br. J. Haematol. 2001, 115:807-811.
38. King K.M., Younes A. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma. Expert. Rev. Anticancer. Ther. 2001, 1(2):177-186.
39. Byrd J.C., et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. JCO 1999, 17(3):791.
40. Gürcan H.M., et al. A review of the current use of rituximab in autoimmune diseases. Int. Immunopharmacol. 2009, 9:10-25.
41. Eisenberg R. Update on Rituximab. Ann. Rheum. Dis. 2005, 64(Supplement 4):55-57.
42. Cree B.A.C., et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005, 64(7):1270-1272.
43. Friedrichs B., et al. The effects of rituximab treatment during pregnancy on a neonate. Haematologica 2006, 91:1426-1427.
44. Golay J., et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000, 95(12):3900-3908.
45. Nahta R., Esteva F.J. Herceptin: mechanisms of action and resistance. Cancer Lett. 2006, 232:123-138.
46. Cosimo S.D., Baselga J. Targeted therapies in breast cancer: where are we now?. Eur. J. Cancer 2008, 44:2781-2790.
47. Scott A.M., et al. Antibody therapy of cancer. Nat. Rev. Cancer 2012, 12:278-287.
48. Slamon D.J., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344:783-792.
49. Martín M., et al. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. Oncologist 2009, 14:1-11.
50. Dean-Colomb W., Esteva F.J. Her2-positive breast cancer: Herceptin and beyond. Eur. J. Cancer 2008, 44:2806-2812.
51. Gelmon K.A., et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin. Breast Cancer 2004, 5(1):52-58.
52. Topalian S.L., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 2443-2454.
53. Drake C.G., et al. Safety, Durable Clinical Benefit, and Remission Resulting from Nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a Phase 1 Trial in Patients with Previously Treated Metastatic Renal Cell Carcinoma (mRCC); Long-term Patient Follow-up 2014.
54. Postwo M.A., et al. Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab. J. Transl. Med. 2014, 12(1):O8.
55. Ofuji K., et al. Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma. J. Hepatocellular Carcinoma 2014, 1:35-42.
56. Morin P.J. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res. 2005, 65(21):9603-9606.
57. Kumar S.K., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111(5):2516-2520.
58. Tai Y., et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood 2014, 123(20):3128-3138.
59. Gattinoni L., et al. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 2006, 6(5):383-393.
60. D. Chung and e. al., "A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy," Journal of Immunology Research, vol. Not yet published, 2014.
61. Mattarollo S.R., et al. Chemotherapy pretreatment sensitizes solid tumor-derived cell lines to Vα24+ NKT cell-mediated cytotoxicity. Int. J. Cancer 2006, 119(7):147-153.
62. Kim T., et al. Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model. Clin. Vaccine Immunol. 2010, 17(1):147-153.
63. Fadul C.E., et al. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J. Immunother. 2011, 34(4):382-389.
64. Kabilova T.O., et al. Immunotherapy of hepatocellular carcinoma with small double-stranded RNA. BMC Cancer 2014, 14(338).
65. Pejawar-Gaddy S., Finn O.J. Cancer vaccines: accomplishments and challenges. Crit. Rev. Oncol. Hematol. 2008, 67(2):93-102.
66. Mitchell D.A., Nair S.K. RNA-transfected dendritic cells in cancer immunotherapy. J. Clin. Invest. 2000, 106(9):1065-1069.
67. Van Nuffel A.M.T., et al. Loading of dendritic cells for immunotherapy. ISBT Sci. Ser. Int. J. Intracell. Transp. 2013, 8(1):161-164.
68. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J. Natl. Cancer Inst. 1990, 82(1):4-7.
69. Criscitiello M.F. What the Shark Immune System Can and Cannot Provide for the Expanding Design Landscape of Immunotherapy 2014, ([Online]).
70. L.C.L., et al. Evaluation of shark cartilage in patients with advanced cancer: a north central cancer treatment group trial. Cancer 2005, 104(1):176-182.
71. C.M.F., et al. An evolutionarily mobile antigen receptor variable region gene: doubly rearranging NAR-TcR genes in sharks. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(13):5036-5041.
72. Weiner L.M., et al. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 2010, 10:317-327.
73. Deonarain M.P., et al. Antibodies targeting cancer stem cells. mAbs 2009, 1(1):12-26.
74. L. Gammaitoni and e. al., "Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective," Expert Opin. Biol. Ther., vol. Not yet published, 2014.
75. Khan K.D., et al. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. Clin. Cancer Res. 2006, 12:7046-7053.
76. Metelitsa L.S., et al. Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody dependent cellular cytotoxicity and depends on FcγRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil gra. Blood 2002, 99:4166-4173.
77. Jahrsdorfer B., Weiner G.J. Immunostimulatory CpG oligodeoxynucleotides and antibody therapy of cancer. Semin. Oncol. 2008, 30:476-482.